Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupSMHGF -9.36%96 3-Year EBITDA Growth Rate is 19.90% as of Dec. 2025, which is 164% above its 10-year median of 7.55. GuruFocus rates SMHGF with a GF Score™ of 96/100 and a GF Value™ of $1.42. Among 808 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 67.45% on this metric.
During the past 12 months, Simcere Pharmaceutical Group's average EBITDA Per Share Growth Rate was 71.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Simcere Pharmaceutical Group was 20.70% per year. The lowest was -14.00% per year. And the median was 7.55% per year.
Simcere Pharmaceutical Group (OTCPK:SMHGF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Simcere Pharmaceutical Group 3-Year EBITDA Growth Rate Related Terms
SMHGF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's 3-Year EBITDA Growth Rate falls into.
Simcere Pharmaceutical Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.90% mean?
Simcere Pharmaceutical Group (SMHGF) has a 3-Year EBITDA Growth Rate of 19.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Simcere Pharmaceutical Group and its competitors. This is 164% above median its historical median of 7.55. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #263 out of 808 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Simcere Pharmaceutical Group's 3-Year EBITDA Growth Rate too high?
Simcere Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 19.90% is 164% above median its 10-year median of 7.55. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Simcere Pharmaceutical Group's value of 19.90% is 123.6% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #263 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #263 out of 808 companies for 3-Year EBITDA Growth Rate. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Simcere Pharmaceutical Group's value of 19.90% is 123.6% above this benchmark. While the company's 10-year median is 7.55 vs. the industry median of 8.90, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current 3-Year EBITDA Growth Rate of 19.90% is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current 3-Year EBITDA Growth Rate is 19.90%, which is 164% above median its own 10-year median of 7.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (SMHGF) has a current 3-Year EBITDA Growth Rate of 19.90%. The stock's GF Value™ is $1.42, compared to a current price of $1.35 — trading 4.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.90%, which is 164% above median its 10-year median of 7.55 and 123.6% above the Drug Manufacturers industry median of 8.90. Simcere Pharmaceutical Group's overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Simcere Pharmaceutical Group (SMHGF), the current 3-Year EBITDA Growth Rate is 19.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (SMHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be undervalued.
The current stock price of $1.35 is trading 4.9% below its estimated GF Value™ of $1.42.
Key valuation signals for SMHGF:
3-Year EBITDA Growth Rate: 19.90% (164% above median its 10-year median of 7.55)
GF Value™: $1.42 vs. price of $1.35 (4.9% below fair value)
Industry Position: 123.6% above the Drug Manufacturers median (#263 of 808)
No single metric tells the full story. See the SMHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
96GF Score
Get the complete analysis for SMHGF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMHGF has been successfully added to your 
